Progress of research on Janus kinase inhibitors in treatment of ulcerative colitis
10.3969/j.issn.1008-7125.2023.04.006
- Author:
Jianshu GAO
1
;
Hongliang GAO
1
Author Information
1. The Second Department of Gastroenterology, the First Affiliated Hospital of Xinjiang Medical University
- Publication Type:Journal Article
- Keywords:
Colitis, Ulcerative;
Efficacy;
Janus Kinases;
Safety
- From:
Chinese Journal of Gastroenterology
2023;28(4):243-248
- CountryChina
- Language:Chinese
-
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease caused by multiple factors, and its etiology and pathogenesis are not fully understood. Janus kinases (JAK) are non‑transmembrane tyrosine kinases that play a key role in many immune‑related cytokine signaling pathways. JAK‑STATs signaling pathway is a cytokine‑mediated signaling pathway, which is involved in many important biological processes such as cell proliferation, differentiation, apoptosis and immune regulation. JAK inhibitors are small molecule drugs that can be administered orally and are relatively inexpensive, therefore, JAK inhibitors may become a new target for the treatment of UC. This article reviewed progress of research on the efficacy and safety of small molecule JAK inhibitors in treatment of UC.
